CO6660496A2 - Nuevos derivados 1.4 diazepanos inhibidores de pde 5 - Google Patents

Nuevos derivados 1.4 diazepanos inhibidores de pde 5

Info

Publication number
CO6660496A2
CO6660496A2 CO12235720A CO12235720A CO6660496A2 CO 6660496 A2 CO6660496 A2 CO 6660496A2 CO 12235720 A CO12235720 A CO 12235720A CO 12235720 A CO12235720 A CO 12235720A CO 6660496 A2 CO6660496 A2 CO 6660496A2
Authority
CO
Colombia
Prior art keywords
diazepane
pde
inhibitors
new derivatives
general formula
Prior art date
Application number
CO12235720A
Other languages
English (en)
Inventor
Armenta Maria Elena Garcia
Ochoa Victor Guillermo Alvarez
Morales Robertos Carlos Osnaya
Barajas Erika Alejandra Zarate
Original Assignee
World Trade Imp Exp Wtie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by World Trade Imp Exp Wtie Ag filed Critical World Trade Imp Exp Wtie Ag
Publication of CO6660496A2 publication Critical patent/CO6660496A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un compuesto de fórmula general ICompuesto de formula general I y un agente coadyuvante, diluyente y/o un acarreador farmacéuticamente aceptable.El disolvente orgánico es seleccionado de entre un grupo de disolventes aromáticos, alifáticos, alicíclicos o dorados y es estable bajo condiciones ácidas y básicas, además no es un inhibidor de la reacción.Agente estimulante se selecciona del grupo que comprende dobesilato de calcio, coenzima Q, L-carnitina y/o L-arginina y sus análogos estructurales.Adicionalmente un agente estimulante de la producción de óxido nítrico.
CO12235720A 2010-06-07 2012-12-28 Nuevos derivados 1.4 diazepanos inhibidores de pde 5 CO6660496A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2010006227A MX2010006227A (es) 2010-06-07 2010-06-07 Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.

Publications (1)

Publication Number Publication Date
CO6660496A2 true CO6660496A2 (es) 2013-04-30

Family

ID=45097594

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12235720A CO6660496A2 (es) 2010-06-07 2012-12-28 Nuevos derivados 1.4 diazepanos inhibidores de pde 5

Country Status (7)

Country Link
EP (1) EP2578588A4 (es)
AR (1) AR081650A1 (es)
BR (1) BR112012031289A2 (es)
CO (1) CO6660496A2 (es)
EC (1) ECSP13012372A (es)
MX (1) MX2010006227A (es)
WO (1) WO2011154798A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102134242B (zh) * 2011-01-21 2013-08-28 浙江大德药业集团有限公司 一种用于治疗阳痿的快速长效的化合物
BR112021009958A2 (pt) * 2018-11-28 2021-08-17 Topadur Pharma Ag modo duplo de ação de ativadores de guanilato ciclase solúveis e inibidores de fosfodiesterase e seus usos

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9612514D0 (en) 1996-06-14 1996-08-14 Pfizer Ltd Novel process
AU748352B2 (en) 1998-04-20 2002-06-06 Pfizer Inc. Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction
CA2235642C (en) 1998-05-15 2007-11-13 Torcan Chemical Ltd. Processes for preparing sildenafil
WO2000024745A1 (en) * 1998-10-23 2000-05-04 Pfizer Limited PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
GB9823101D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
EP1002798A1 (en) 1998-11-20 2000-05-24 Orchid Chemicals & Pharmaceuticals Ltd. An improved process for preparing a therapeutically active pyrazolopyrimidinone derivative
AU5925500A (en) 1999-07-09 2001-01-30 Picower Institute For Medical Research, The Pyrazolopyrimidinone derivatives conjugated to thiophene moieties or benzo [fused] 5-membered heterocycles for erectile dysfunction
EP1077214A1 (en) 1999-08-16 2001-02-21 Orchid Chemicals & Pharmaceuticals Ltd. An improved process for preparing a pyrazolopyrimidinone derivative
AU1888800A (en) 1999-09-13 2001-04-17 Cipla Limited A novel process for the synthesis of sildenafil citrate
MXPA99010322A (es) 1999-11-10 2003-07-15 Europharm S A De C V Proceso para la preparacion de sildenafil.
ES2223863T3 (es) 2000-06-22 2005-03-01 Pfizer Inc. Procedimiento para la preparacion de pirazolopirimidinonas.
ES2310144B1 (es) 2007-06-15 2010-01-12 Galenicum Health, S.L. Intermedios para la preparacion de un inhibidor de la fosfodiesterasa tipo 5.
EA201070056A1 (ru) 2007-06-26 2010-06-30 Солвей Фармасьютикалс Б.В. N-оксид силденафила в качестве пролекарства

Also Published As

Publication number Publication date
ECSP13012372A (es) 2013-02-28
BR112012031289A2 (pt) 2016-11-01
MX2010006227A (es) 2011-12-14
WO2011154798A1 (es) 2011-12-15
EP2578588A1 (en) 2013-04-10
AR081650A1 (es) 2012-10-10
EP2578588A4 (en) 2013-12-04

Similar Documents

Publication Publication Date Title
BR112018070677A2 (pt) inibidores de mcl-1 macrocíclicos para o tratamento de câncer
ES2634490T3 (es) Derivados de ácido napht-2-ylacetico para tratar el sida
AR074845A1 (es) Procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
WO2016077464A8 (en) Amino acid derivatives and their uses
PE20090060A1 (es) ANALOGOS DE IMIDAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE PI3 CINASA Y mTOR
DOP2019000087A (es) Compuestos químicos
CO6251357A2 (es) Nuevos derivados de acido azabifenilaminobenzoico
PA8813101A1 (es) Derivados bicílicos de carboxamidas aza-bicíclicas,su preparación y su aplicación terapéutica
BR112018011788A2 (pt) formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação
AR082444A1 (es) Formulacion farmaceutica que comprende un inhibidor de fosfodiesterasa
PH12015500008A1 (en) Dimethyl-benzoic acid compounds
DOP2010000022A (es) Derivados de pirimidina 934
MX2013000295A (es) Procedimiento de preparacion de un inhibidor especifico de la trombina.
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
PH12015502429A1 (en) Dicarboxylic acid compound
WO2013152277A3 (en) Moenomycin analogs, methods of synthesis, and uses thereof
AR105774A1 (es) Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificación para su uso como principio activo farmacéutico
MX2017005422A (es) Inhibidores de histona desacetilasa y sus usos en terapia.
CL2020003015A1 (es) Conversión a escala preparativa de goniautoxinas en neosaxitoxina
AR107494A1 (es) Proceso para la preparación de osimertinib (azd9291) o una sal del mismo, y “azd9291 anilina” o una sal de la misma
CO6660496A2 (es) Nuevos derivados 1.4 diazepanos inhibidores de pde 5
AR101136A1 (es) Proceso para la preparación de ácidos 3-hidroxipicolínicos
AR073037A1 (es) Derivados de enfumafungina, utiles en la inhibicionde (1,3)-beta-d-glucano sintasa

Legal Events

Date Code Title Description
FA Application withdrawn